Madhav Vasanthavada Sells Shares of Abeona Therapeutics Inc. $ABEO

Key Points

  • Madhav Vasanthavada sold 222 shares of Abeona Therapeutics Inc. ($ABEO) worth $1,258.74.
  • $ABEO last traded around $5.82.

Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.

Madhav Vasanthavada, Chief Commercial Officer at Abeona Therapeutics Inc. ($ABEO), sold 222 shares at an average price of $5.67, for a total transaction of $1,258.74. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.

Abeona Therapeutics Inc. Stock Down 1.7%

Shares of Abeona Therapeutics Inc. ($ABEO) traded around $5.82 on Wednesday, down 1.7% for the day.

Last price$5.82
Market cap$334.53M
Forward P/E-31.34
Beta1.34
52-week low$4
52-week high$7.65
50-day MA$6.40
200-day MA$5.46
Current ratio6.63
Quick ratio6.32
Debt-to-equity0.16

Abeona Therapeutics Inc. Earnings

EPS (ttm)-$1.20
Revenue (ttm)$25.52M
Revenue growth2745%
Net margin-246.42%
Return on equity-43.13%
Next earningsNov 11, 2026

Analysts Set New Price Targets

ConsensusStrong Buy
Average target$18.86
High target$28
Low target$14
Analysts covering7

About Abeona Therapeutics Inc.

Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.

ExchangeNasdaqCM
SectorHealthcare
IndustryBiotechnology
HeadquartersCleveland, OH
CEODr. Vishwas Seshadri M.B.A., Ph.D.
Employees226

Get Abeona Therapeutics Inc. alerts

New 13F filings, insider trades, and analyst moves on $ABEO, sent to your inbox. Free, and you can unsubscribe anytime.

This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.